Pharmacodynamics and Pharmacokinetics of P-3074, a New Finasteride Topical Solution, Administered at Four Different Doses

Topical finasteride (P-3074) can inhibit scalp DHT by up to 70%, with some users experiencing systemic absorption similar to oral use. Users discuss varying application frequencies and concentrations, with some noticing side effects when overused.

A 19-year-old used a 0.01% topical finasteride formula, which unexpectedly lowered DHT levels significantly. They are considering reducing the dose further and exploring alternatives like ketoconazole shampoo, KX826, and CB to manage hair loss while minimizing systemic absorption.

The user is using a regimen of topical finasteride (.025% concentration), minoxidil, Nutrafol, and vitamin D to address hair loss. They experienced initial side effects but reported improvement over 11 weeks and are considering increasing the dosage.

A 23-year-old male with slight hair thinning is using ketoconazole shampoo, biotin, zinc, magnesium, D3/K2, and has just started topical finasteride (0.0125%). He plans to add minoxidil (4.5%) with 17α-estradiol and is seeking advice on the effectiveness and side effects of these treatments, as well as the use of a dermaroller.

Topical dutasteride 0.05% is more effective for hair growth than oral finasteride 1mg, with minimal DHT reduction. The formulation uses castor oil and MCTs for better absorption but is not widely available until 2028.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.